Loading stock data…
$1.50-0.06 (-3.85%)
Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally.
Femasys Inc. in the Healthcare sector is trading at $1.50 with a market capitalization of $21M. Wall Street consensus targets $14.33 (3 analysts), implying a +855.6% move over the next 12 months. The stock is currently near its 52-week low of $1.46, remaining 76.6% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 28 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $331,827↓ | $424,889↓ | $813,387↑ | $729,394↑ | $409,268 |
| Gross Profit | $189,391↓ | $266,283↓ | $510,262↑ | $435,556↑ | $251,097 |
| Operating Income | -$5.07M↓ | -$4.22M↑ | -$4.62M↓ | -$3.65M↑ | -$3.85M |
| Net Income | -$4.47M↓ | $846,100↑ | -$3.95M↑ | -$4.19M↑ | -$4.59M |
Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue...